Contact Us    |      Join    |

"The Voice of Oncology in Massachusetts"

FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma

March 24, 2023 9:53 AM | Katy Monaco (Administrator)

FDA granted accelerated approval to retifanlimab-dlwr (Zynyz, Incyte Corporation) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).  Read More.  View full prescribing information for Zynyz.



ADDRESS

860 Winter Street, Waltham, MA, 02451

CONTACT US

tel: 781.434.7329

msco@mms.org

Massachusetts Society of Clinical Oncologists ©2024

Powered by Wild Apricot Membership Software